Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy.

Breast Dose tolerance Fibrosis Skin reactions

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
27 Feb 2024
Historique:
received: 10 10 2023
revised: 17 02 2024
accepted: 20 02 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: aheadofprint

Résumé

Toxicity after whole breast Radiotherapy is a relevant issue, impacting the quality-of-life of a not negligible number of patients. We aimed to develop a Normal Tissue Complication Probability (NTCP) model predicting late toxicities by combining dosimetric parameters of the breast dermis and clinical factors. The skin structure was defined as the outer CT body contour's 5 mm inner isotropic expansion. It was retrospectively segmented on a large mono-institutional cohort of early-stage breast cancer patients enrolled between 2009 and 2017 (n = 1066). Patients were treated with tangential-field RT, delivering 40 Gy in 15 fractions to the whole breast. Toxicity was reported during Follow-Up (FU) using SOMA/LENT scoring. The study endpoint was moderate-severe late toxicity consisting of Fibrosis-Atrophy-Telangiectasia-Pain (FATP G ≥ 2) developed within 42 months after RT completion. A machine learning pipeline was designed with a logistic model combining clinical factors and absolute skin DVH (cc) parameters as output. The FATP G2 + rate was 3.8 %, with 40/1066 patients experiencing side effects. After the preprocessing of variables, a cross-validation was applied to define the best-performing model. We selected a 4-variable model with Post-Surgery Cosmetic alterations (Odds Ratio, OR = 7.3), Aromatase Inhibitors (as a protective factor with OR = 0.45), V20 Gy (50 % of the prescribed dose, OR = 1.02), and V42 Gy (105 %, OR = 1.09). Factors were also converted into an adjusted V20Gy. The association between late reactions and skin DVH when delivering 40 Gy/15 fr was quantified, suggesting an independent role of V20 and V42. Few clinical factors heavily modulate the risk.

Sections du résumé

BACKGROUND BACKGROUND
Toxicity after whole breast Radiotherapy is a relevant issue, impacting the quality-of-life of a not negligible number of patients. We aimed to develop a Normal Tissue Complication Probability (NTCP) model predicting late toxicities by combining dosimetric parameters of the breast dermis and clinical factors.
METHODS METHODS
The skin structure was defined as the outer CT body contour's 5 mm inner isotropic expansion. It was retrospectively segmented on a large mono-institutional cohort of early-stage breast cancer patients enrolled between 2009 and 2017 (n = 1066). Patients were treated with tangential-field RT, delivering 40 Gy in 15 fractions to the whole breast. Toxicity was reported during Follow-Up (FU) using SOMA/LENT scoring. The study endpoint was moderate-severe late toxicity consisting of Fibrosis-Atrophy-Telangiectasia-Pain (FATP G ≥ 2) developed within 42 months after RT completion. A machine learning pipeline was designed with a logistic model combining clinical factors and absolute skin DVH (cc) parameters as output.
RESULTS RESULTS
The FATP G2 + rate was 3.8 %, with 40/1066 patients experiencing side effects. After the preprocessing of variables, a cross-validation was applied to define the best-performing model. We selected a 4-variable model with Post-Surgery Cosmetic alterations (Odds Ratio, OR = 7.3), Aromatase Inhibitors (as a protective factor with OR = 0.45), V20 Gy (50 % of the prescribed dose, OR = 1.02), and V42 Gy (105 %, OR = 1.09). Factors were also converted into an adjusted V20Gy.
CONCLUSIONS CONCLUSIONS
The association between late reactions and skin DVH when delivering 40 Gy/15 fr was quantified, suggesting an independent role of V20 and V42. Few clinical factors heavily modulate the risk.

Identifiants

pubmed: 38423138
pii: S0167-8140(24)00104-X
doi: 10.1016/j.radonc.2024.110183
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110183

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alessandro Cicchetti (A)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Data Science Unit, Milan, Italy. Electronic address: alessandro.cicchetti@istitutotumori.mi.it.

Paola Mangili (P)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Andrei Fodor (A)

IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy.

Maria Giulia Ubeira Gabellini (MGU)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Anna Chiara (A)

IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy.

Chiara Deantoni (C)

IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy.

Martina Mori (M)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Marcella Pasetti (M)

IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy.

Gabriele Palazzo (G)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Tiziana Rancati (T)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Data Science Unit, Milan, Italy.

Antonella Del Vecchio (A)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Nadia Gisella Di Muzio (N)

IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy.

Claudio Fiorino (C)

IRCCS San Raffaele Scientific Institute, Medical Physics Milan, Italy.

Classifications MeSH